Pediatric AIDS (PAIDS) presents with distinct clinical and immunologic features, differing from congenital immunodeficiencies. Research suggests a common cause for PAIDS, necessitating further investigation into etiology and treatment.
Area of Science:
Pediatric Immunology
Infectious Diseases
Virology
Background:
Describes approximately 40-50 infants and children with similar epidemiologic, clinical, and laboratory features of Acquired Immunodeficiency Syndrome (AIDS).
Highlights the geographic clustering and shared risk factors in patients with Pediatric AIDS (PAIDS), suggesting a common etiology.
Differentiates PAIDS from congenital immunodeficiency disorders based on clinical and laboratory findings.
Purpose of the Study:
To investigate the immunologic profile of infants and children diagnosed with PAIDS.
To explore potential causative agents and risk factors associated with PAIDS.
To identify differences between PAIDS and congenital immunodeficiencies, particularly in maternal immune status.
Main Methods:
Immunologic evaluation including assessment of immunoglobulin levels, antibody responses, T-cell counts, helper/suppressor cell ratios, and T-cell functional studies.
Clinical and laboratory feature comparison between PAIDS patients and those with congenital immunodeficiency disorders.
Serologic testing for viral agents, specifically antibodies to ARV and HTLV-III.
Main Results:
Immunologic findings in PAIDS include hypergammaglobulinemia, impaired antibody responses, altered T-cell numbers, decreased helper/suppressor ratios, and abnormal T-cell function.
No patients exhibited features of established congenital immunodeficiencies.
Antibodies to ARV and HTLV-III were the only consistent viral agents found; mothers of PAIDS infants frequently showed T-cell abnormalities, unlike mothers of infants with congenital immunodeficiencies.
Conclusions:
PAIDS presents a distinct clinical and immunological syndrome in children.
The findings suggest a common infectious cause for PAIDS, potentially linked to ARV and HTLV-III.
Future research should focus on elucidating PAIDS etiology, risk factors, and effective immunologic reconstitution therapies.